A Nonpolycationic Fully Proteinaceous Multiagent System for Potent Targeted Delivery of siRNA.

A Nonpolycationic Fully Proteinaceous Multiagent System for Potent Targeted Delivery of siRNA.
复制标题

DOI:
10.1038/mtna.2014.14
复制
发表时间:
2014-05-13
期刊:
Molecular therapy. Nucleic acids
影响因子:
--
通讯作者:
--
中科院分区:
其他
文献类型:
--
作者:

文献摘要

参考文献

被引文献

相似文献

靶向短干扰RNA(siRNA)递送的基于蛋白质的方法具有解决基于纳米颗粒的方法所面临的一些问题的潜力,例如差的药代动力学和生物分布、低肿瘤穿透性和多分散性。然而,基于蛋白质的靶向递送限于具有聚阳离子肽作为siRNA载体的融合蛋白,其高电荷密度在某些情况下导致不期望的生物物理和体内性质。在这里,我们提出了一个完全蛋白质,多代理人的方法,靶向siRNA交付表皮生长因子受体(EGFR),使用非聚阳离子载体的siRNA。每种药物都有一种根本不同的作用机制,共同作用于有效的靶向RNA干扰。第一种试剂是EGFR靶向融合蛋白,其使用双链RNA结合结构域作为非聚阳离子siRNA载体。该双链RNA结合结构域融合蛋白可以将siRNA递送至EGFR表达细胞系的内体。第二种试剂以靶向方式递送胆固醇依赖性溶细胞素,产气荚膜梭菌溶素0,其增强siRNA的内体逃逸并诱导基因沉默。聚集EGFR的第三种药物增加基因沉默效力并降低溶细胞素毒性。总而言之,该系统是有效的,基因沉默仅需要16 nmol/l siRNA,并且治疗窗口跨越两个数量级的靶向溶细胞素浓度。
Protein-based methods of targeted short-interfering RNA (siRNA) delivery have the potential to solve some of the problems faced by nanoparticle-based methods, such as poor pharmacokinetics and biodistribution, low tumor penetration, and polydispersity. However, protein-based targeted delivery has been limited to fusion proteins with polycationic peptides as siRNA carriers, whose high charge density in some cases results in undesirable biophysical and in vivo properties. Here, we present a fully proteinaceous, multiagent approach for targeted siRNA delivery to epidermal growth factor receptor (EGFR), using a nonpolycationic carrier for siRNA. Each agent contributes a fundamentally different mechanism of action that work together for potent targeted RNA interference. The first agent is an EGFR-targeted fusion protein that uses a double-stranded RNA-binding domain as a nonpolycationic siRNA carrier. This double-stranded RNA-binding domain fusion protein can deliver siRNA to the endosomes of an EGFR-expressing cell line. A second agent delivers the cholesterol-dependent cytolysin, perfringolysin O, in a targeted manner, which enhances the endosomal escape of siRNA and induces gene silencing. A third agent that clusters EGFR increases gene-silencing potency and decreases cytolysin toxicity. Altogether, this system is potent, with only 16 nmol/l siRNA required for gene silencing and a therapeutic window that spans two orders of magnitude of targeted cytolysin concentrations.
DOI: 10.2144/01311st05
发表时间: 2001-07-01
期刊: BIOTECHNIQUES
影响因子: 2.7
作者:
Geiser, M;Cèbe, R;Schmitz, R
通讯作者: Schmitz, R
DOI: 10.1021/mp800051m
发表时间: 2008-07
影响因子: 4.9
作者:
Alexis F;Pridgen E;Molnar LK;Farokhzad OC
通讯作者: Farokhzad OC
DOI: 10.1097/cji.0b013e3181b528da
发表时间: 2009-11
期刊: Journal of immunotherapy (Hagerstown, Md. : 1997)
影响因子: --
作者:
Liu DV;Maier LM;Hafler DA;Wittrup KD
通讯作者: Wittrup KD
由siRNA结合融合蛋白介导的基因沉默被双链RNA结合结构域结构减弱。
DOI: 10.1038/mtna.2012.43
发表时间: 2012-11-13
期刊: Molecular therapy. Nucleic acids
影响因子: --
作者:
通讯作者: --
DOI: 10.1111/j.1462-5822.2008.01191.x
发表时间: 2008-09
影响因子: 3.4
作者:
Rosado CJ;Kondos S;Bull TE;Kuiper MJ;Law RH;Buckle AM;Voskoboinik I;Bird PI;Trapani JA;Whisstock JC;Dunstone MA
通讯作者: Dunstone MA